AMENDMENT NO. 1 TO AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGERAgreement and Plan of Merger • February 13th, 2023 • Oncocyte Corp • In vitro & in vivo diagnostic substances
This AMENDMENT NO. 1 TO AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER, dated as of February 8, 2023 (this “Amendment No. 1”), is entered into by and between Oncocyte Corporation, a California corporation (“Parent”) and David MacKenzie, solely in his capacity as Equityholder Representative (the “Equityholder Representative”). Initially capitalized terms used in this Amendment No. 1 and not otherwise defined will have the meanings set forth in the Merger Agreement (as defined below).
TERMINATION AGREEMENTTermination Agreement • February 13th, 2023 • Oncocyte Corp • In vitro & in vivo diagnostic substances • California
This Termination Agreement (“Termination Agreement”) is made and dated as of the date of the last signature below (the “Effective Date”), by and between Life Technologies Corporation, having a place of business at 5823 Newton Drive, Carlsbad, California 92008 (“LTC”); and Oncocyte Corporation, a California corporation having a place of business at 15 Cushing, Irvine, California 92618 (“Oncocyte”). Hereinafter, each of LTC and Oncocyte are referred to as a “Party” and collectively as the “Parties” to this Termination Agreement.
